MA38393B1 - Composés hétéroaryle et utilisations associées - Google Patents
Composés hétéroaryle et utilisations associéesInfo
- Publication number
- MA38393B1 MA38393B1 MA38393A MA38393A MA38393B1 MA 38393 B1 MA38393 B1 MA 38393B1 MA 38393 A MA38393 A MA 38393A MA 38393 A MA38393 A MA 38393A MA 38393 B1 MA38393 B1 MA 38393B1
- Authority
- MA
- Morocco
- Prior art keywords
- protein kinase
- heteroaryl compounds
- related uses
- compositions
- carcinomas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
L'invention concerne des composés utiles comme inhibiteurs de protéines kinases, contenant un reste de cystéine dans le site de liaison atp. L'invention concerne également des compositions pharmaceutiquement acceptables comprenant des quantités thérapeutiquement efficaces d'un ou de plusieurs composés inhibiteurs de protéines kinases, ainsi que des méthodes d'utilisation de ces compositions dans le traitement de cancers et de carcinomes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14305361 | 2014-03-13 | ||
PCT/US2014/029270 WO2014144737A1 (fr) | 2013-03-15 | 2014-03-14 | Composés hétéroaryle et utilisations associées |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38393A3 MA38393A3 (fr) | 2018-05-31 |
MA38393B1 true MA38393B1 (fr) | 2018-11-30 |
Family
ID=50390019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38393A MA38393B1 (fr) | 2014-03-13 | 2014-03-14 | Composés hétéroaryle et utilisations associées |
Country Status (13)
Country | Link |
---|---|
US (1) | US9663524B2 (fr) |
EP (1) | EP2968337B1 (fr) |
JP (1) | JP6576325B2 (fr) |
KR (1) | KR102219695B1 (fr) |
CN (2) | CN111793068A (fr) |
AU (1) | AU2014228746B2 (fr) |
BR (1) | BR112015022191A8 (fr) |
EA (1) | EA036160B1 (fr) |
MA (1) | MA38393B1 (fr) |
MX (1) | MX2015011514A (fr) |
PE (1) | PE20151776A1 (fr) |
SG (1) | SG11201507478VA (fr) |
WO (1) | WO2014144737A1 (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
IL289834B1 (en) | 2012-06-13 | 2024-03-01 | Incyte Holdings Corp | Conversion of tricyclic compounds as FGFR inhibitors |
WO2014011900A2 (fr) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibiteurs du récepteur du facteur de croissance de fibroblastes |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
EP3943087A1 (fr) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Composés hétéroaryle et utilisations associées |
AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
DK3057943T3 (en) | 2013-10-18 | 2018-07-30 | Eisai R&D Man Co Ltd | PYRIMIDINE-FGFR4 INHIBITORS |
US9266883B2 (en) | 2013-10-25 | 2016-02-23 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
HUE059037T2 (hu) | 2013-10-25 | 2022-10-28 | Blueprint Medicines Corp | Fibroblaszt növekedési faktor receptor gátlók |
US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
WO2016014542A1 (fr) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs d'imidazolyl kinase et leurs utilisations |
WO2016014551A1 (fr) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase macrocycliques et leurs utilisations |
CA2955082A1 (fr) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Utilisations d'inhibiteurs de kinases inductibles par un sel (sik) |
PL3200786T3 (pl) | 2014-10-03 | 2020-03-31 | Novartis Ag | Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MX2017010673A (es) | 2015-02-20 | 2018-03-21 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
US10189813B2 (en) | 2015-03-25 | 2019-01-29 | Novartis Ag | Formylated N-heterocyclic derivatives as FGFR4 inhibitors |
MX2017013248A (es) | 2015-04-14 | 2018-07-06 | Eisai R&D Man Co Ltd | Compuesto del inhibidor fgfr4 cristalino y usos del mismo. |
JP7372740B2 (ja) | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ |
KR20180002053A (ko) * | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
US10954242B2 (en) * | 2016-07-05 | 2021-03-23 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
WO2018055503A1 (fr) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combinaison comprenant un antagoniste de pd-1 et un inhibiteur de fgfr4 |
WO2018083603A1 (fr) | 2016-11-02 | 2018-05-11 | Novartis Ag | Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire |
WO2018113584A1 (fr) * | 2016-12-19 | 2018-06-28 | 上海和誉生物医药科技有限公司 | Inhibiteur de fgfr4, son procédé de préparation et son utilisation pharmaceutique |
EP3589284A4 (fr) | 2017-02-28 | 2020-12-16 | The General Hospital Corporation | Utilisations de pyrimidopyrimidinones comme inhibiteurs de sik |
CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
US11174255B2 (en) * | 2017-05-15 | 2021-11-16 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
WO2019015593A1 (fr) * | 2017-07-19 | 2019-01-24 | 江苏奥赛康药业股份有限公司 | Composé de pyrimidopyridone ou pyridopyridone et utilisation correspondante |
WO2019029541A1 (fr) * | 2017-08-08 | 2019-02-14 | 南京药捷安康生物科技有限公司 | Inhibiteur de récepteur du facteur de croissance des fibroblastes et son utilisation |
CN109745325B (zh) * | 2017-11-08 | 2022-02-15 | 上海翰森生物医药科技有限公司 | Fgfr4抑制剂、其制备方法和用途 |
CN110386921A (zh) * | 2018-04-23 | 2019-10-29 | 南京药捷安康生物科技有限公司 | 成纤维细胞生长因子受体抑制剂化合物 |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
WO2019223766A1 (fr) * | 2018-05-25 | 2019-11-28 | 上海和誉生物医药科技有限公司 | Inhibiteur de fgfr, son procédé de préparation et son utilisation pharmaceutique |
CN110577524B (zh) * | 2018-06-07 | 2022-01-28 | 北京大学深圳研究生院 | 一种激酶选择性抑制剂 |
WO2019242587A1 (fr) * | 2018-06-19 | 2019-12-26 | 上海和誉生物医药科技有限公司 | Inhibiteur hautement sélectif de fgfr i, son procédé de préparation et son utilisation |
CN112119064B (zh) * | 2018-09-14 | 2023-06-23 | 上海和誉生物医药科技有限公司 | Fgfr抑制剂、其制备方法和应用 |
KR20210131369A (ko) * | 2019-03-08 | 2021-11-02 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | Fgfr4 키나아제 억제제 및 이의 제조 방법과 용도 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (fr) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Fgfr阻害剤としての二環式複素環 |
WO2021076728A1 (fr) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
GB201915828D0 (en) * | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
WO2021108803A1 (fr) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Composés de pyrimidine pyridinone fusionnés en tant qu'inhibiteurs de jak |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
CA3213379A1 (fr) * | 2021-03-26 | 2022-09-29 | Weiqiang Zhan | Inhibiteur de fgfr4 heterocyclique bicyclique, composition pharmaceutique, preparation le comprenant, et utilisation associee |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
CN113527311B (zh) * | 2021-08-23 | 2022-05-06 | 中南大学湘雅医院 | Fgfr4抑制剂、组合物及其在药物制备中的用途 |
WO2023039828A1 (fr) * | 2021-09-17 | 2023-03-23 | Nutshell Biotech (Shanghai) Co., Ltd. | Composés cycliques fusionnés utiles en tant qu'inhibiteurs de tyrosine kinases fgfr4 |
CN113912602B (zh) * | 2021-10-14 | 2023-05-05 | 温州医科大学 | 一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
TJ342B (en) * | 1994-11-14 | 2002-10-06 | Warner Lambert Co | Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
BR9807305A (pt) | 1997-02-05 | 2000-05-02 | Warner Lambert Co | Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular. |
DE19802377A1 (de) | 1998-01-22 | 1999-08-19 | Max Planck Gesellschaft | Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs |
NZ508268A (en) | 1998-05-26 | 2004-02-27 | Warner Lambert Co | Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation |
PL347432A1 (en) | 1998-10-23 | 2002-04-08 | Hoffmann La Roche | Bicyclic nitrogen heterocycles |
MXPA02001108A (es) | 1999-09-15 | 2002-08-20 | Warner Lambert Co | Pieridinonas como inhibidores de la cinasa. |
AU776695B2 (en) | 1999-10-21 | 2004-09-16 | F. Hoffmann-La Roche Ag | Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
IL149100A0 (en) | 1999-10-21 | 2002-11-10 | Hoffmann La Roche | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
AR030053A1 (es) | 2000-03-02 | 2003-08-13 | Smithkline Beecham Corp | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas |
DE60135854D1 (de) * | 2000-08-04 | 2008-10-30 | Warner Lambert Co | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-one |
KR100571339B1 (ko) | 2000-08-31 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 세포증식 억제제로서의 7-옥소 피리도피리미딘 |
US6506749B2 (en) | 2000-08-31 | 2003-01-14 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (I) |
CN100358892C (zh) | 2000-08-31 | 2008-01-02 | 霍夫曼-拉罗奇有限公司 | 7-氧代吡啶并嘧啶 |
US6518276B2 (en) | 2000-08-31 | 2003-02-11 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (II) |
WO2002076985A1 (fr) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives |
WO2003000657A1 (fr) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
AU2003250475A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
US7084270B2 (en) | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
TW200413381A (en) | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
US7098332B2 (en) * | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
AU2003301226A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corp | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
WO2004063195A1 (fr) | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Inhibiteurs de kinases a base de pyridopyrimidine |
BRPI0409366A (pt) | 2003-04-10 | 2006-04-25 | Hoffmann La Roche | compostos de pirimido |
MXPA05011103A (es) | 2003-04-16 | 2005-12-12 | Hoffmann La Roche | Compuestos de quinazolina. |
BRPI0413005A (pt) * | 2003-07-29 | 2006-09-26 | Irm Llc | compostos e composições como inibidores da proteìna cinase |
EP1673343A4 (fr) | 2003-10-08 | 2008-09-10 | Irm Llc | Composes et compositions convenant comme inhibiteurs de proteine-kinases |
WO2005066211A2 (fr) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Utilisation des recepteurs 1, 2, 3 et 4 du facteur de croissance des fibroblastes comme cibles pour une intervention therapeutique |
JP5520433B2 (ja) | 2004-01-21 | 2014-06-11 | エモリー ユニバーシティー | 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用 |
WO2005105097A2 (fr) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Derives de pyridopyrimidine |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
CA2576924A1 (fr) | 2004-08-31 | 2006-03-09 | F. Hoffmann-La Roche Ag | Derives amide de 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, ainsi que leur preparation et leur utilisation en tant qu'inhibiteurs de la proteine kinase |
CN101048388A (zh) | 2004-08-31 | 2007-10-03 | 阿斯利康(瑞典)有限公司 | 喹唑啉酮衍生物及其作为B-Raf抑制剂的用途 |
DE602005013248D1 (de) | 2004-08-31 | 2009-04-23 | Hoffmann La Roche | Amidderivate von 3-phenyldihydropyrimidoä4,5-düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel |
WO2006038112A1 (fr) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Utilisation d'inhibiteurs de kinases pour favoriser la neochondrogenese |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
JP5111113B2 (ja) | 2004-12-13 | 2012-12-26 | サネシス ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン |
US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
JP5079500B2 (ja) | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | 2−アミノキナゾリン誘導体 |
CN101238129A (zh) | 2005-06-10 | 2008-08-06 | Irm责任有限公司 | 维持胚胎干细胞多能性的化合物 |
WO2006137421A1 (fr) | 2005-06-21 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent pour administration topique |
WO2007014123A2 (fr) | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions et procedes de traitement de maladies a l'aide de proteines de fusion fgfr |
EP1906967A4 (fr) | 2005-07-26 | 2010-07-28 | Vertex Pharma | Inhibition de kinase d'abl |
KR100832593B1 (ko) | 2005-11-08 | 2008-05-27 | 한미약품 주식회사 | 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법 |
US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
MEP3808A (xx) | 2005-12-21 | 2010-02-10 | Novartis Ag | Derivati pirimidinil aril uree kao fgf inhibitori |
AU2006331765A1 (en) | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor |
RU2008148607A (ru) | 2006-05-11 | 2010-06-20 | Айрм Ллк (Bm) | Соединения и композиции в качестве ингибиторов протеинкиназы |
US20090312321A1 (en) | 2006-05-15 | 2009-12-17 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
EP1914234A1 (fr) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases |
AU2007311480A1 (en) | 2006-10-16 | 2008-04-24 | Forma Therapeutics, Inc. | Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors |
WO2008150260A1 (fr) | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | Inhibiteurs de kinase |
WO2008051820A2 (fr) | 2006-10-20 | 2008-05-02 | Swagelok Company | Amorçage d'arc à courant continu avec entrée universelle |
WO2008055842A1 (fr) | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Dérivés de 6-phényl-pyrido [2,3-d] pyrimidine-7-one substitués utilisés comme inhibiteurs de la kinase et méthodes d'utilisation de ceux-ci |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
WO2008078091A1 (fr) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr |
PT2132194E (pt) | 2006-12-27 | 2011-05-16 | Sanofi Aventis | Isoquinolinas substitu?das e sua utiliza??o como inibidores de rho-cinase |
WO2008077556A1 (fr) * | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Dérivés d'isoquinoline et d'isoquinolinone substitués par une cycloalkylamine |
EP2168966B1 (fr) | 2007-06-15 | 2016-09-28 | Msd K.K. | Dérivé d'aniline bicyclique |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
US8216783B2 (en) | 2008-04-14 | 2012-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors |
EP2112150B1 (fr) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Inhibiteurs Raf améliorés |
CN102015660A (zh) | 2008-04-23 | 2011-04-13 | 协和发酵麒麟株式会社 | 2-氨基喹唑啉衍生物 |
UA103478C2 (ru) | 2008-05-23 | 2013-10-25 | Новартіс Аг | Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы |
US20100121052A1 (en) | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
CA2986640C (fr) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Composes hetero-aryles et leurs utilisations |
KR101341876B1 (ko) * | 2008-09-05 | 2013-12-20 | 셀진 아빌로믹스 리서치, 인코포레이티드 | 비가역 인히비터 디자인을 위한 알고리즘 |
EP2376493B1 (fr) | 2008-12-12 | 2016-10-05 | Msd K.K. | Dérivé de dihydropyrimidopyrimidine |
AU2009325400A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivatives |
US9266890B2 (en) | 2009-01-06 | 2016-02-23 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
EP2478361A4 (fr) | 2009-09-16 | 2014-05-21 | Celgene Avilomics Res Inc | Conjugués et inhibiteurs de protéine kinase |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
AR079257A1 (es) | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
JP2013514986A (ja) | 2009-12-18 | 2013-05-02 | ノバルティス アーゲー | 血液癌の処置方法 |
GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
JP2014511395A (ja) * | 2011-03-09 | 2014-05-15 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Pi3キナーゼインヒビターおよびその使用 |
EP2694551A1 (fr) | 2011-04-07 | 2014-02-12 | Genentech, Inc. | Anticorps anti-fgfr4 et procédés d'utilisation |
KR102052670B1 (ko) | 2011-05-17 | 2019-12-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키나아제 저해제 |
CN102887895B (zh) | 2011-07-22 | 2016-08-24 | 山东轩竹医药科技有限公司 | 吡啶并嘧啶类mTOR抑制剂 |
BR112014010420A2 (pt) | 2011-11-04 | 2017-04-25 | Afraxis Holdings Inc | inibidores de pak para o tratamento de distúrbios proliferativos celulares |
CA2875970C (fr) | 2012-06-07 | 2017-07-04 | Deciphera Pharmaceuticals, Llc | Dihydronaphtyridines et composes apparentes utiles comme inhibiteurs de kinases pour le traitement de maladies proliferatives |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
WO2014011900A2 (fr) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibiteurs du récepteur du facteur de croissance de fibroblastes |
TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
EP2970231A1 (fr) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Dérivés de pipérazine et leur utilisation comme modulateurs de kit |
TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
AU2014287209B2 (en) | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
EP3027655B1 (fr) | 2013-07-30 | 2019-08-21 | Blueprint Medicines Corporation | Fusions de ntrk2 |
US10875930B2 (en) | 2013-07-30 | 2020-12-29 | Blueprint Medicines Corporation | PIK3C2G fusions |
WO2015058129A1 (fr) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Composés à utiliser pour traiter des troubles associés à l'enzyme kit |
HUE059041T2 (hu) | 2013-10-17 | 2022-10-28 | Blueprint Medicines Corp | Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására |
DK3057943T3 (en) | 2013-10-18 | 2018-07-30 | Eisai R&D Man Co Ltd | PYRIMIDINE-FGFR4 INHIBITORS |
HUE059037T2 (hu) | 2013-10-25 | 2022-10-28 | Blueprint Medicines Corp | Fibroblaszt növekedési faktor receptor gátlók |
US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
-
2014
- 2014-03-14 AU AU2014228746A patent/AU2014228746B2/en not_active Ceased
- 2014-03-14 CN CN202010661205.XA patent/CN111793068A/zh active Pending
- 2014-03-14 EP EP14763001.6A patent/EP2968337B1/fr active Active
- 2014-03-14 MX MX2015011514A patent/MX2015011514A/es active IP Right Grant
- 2014-03-14 US US14/776,373 patent/US9663524B2/en active Active
- 2014-03-14 CN CN201480016170.7A patent/CN105307657B/zh active Active
- 2014-03-14 WO PCT/US2014/029270 patent/WO2014144737A1/fr active Application Filing
- 2014-03-14 PE PE2015002022A patent/PE20151776A1/es unknown
- 2014-03-14 SG SG11201507478VA patent/SG11201507478VA/en unknown
- 2014-03-14 KR KR1020157029048A patent/KR102219695B1/ko active IP Right Grant
- 2014-03-14 JP JP2016503031A patent/JP6576325B2/ja active Active
- 2014-03-14 MA MA38393A patent/MA38393B1/fr unknown
- 2014-03-14 EA EA201591420A patent/EA036160B1/ru not_active IP Right Cessation
- 2014-03-14 BR BR112015022191A patent/BR112015022191A8/pt active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
MX2015011514A (es) | 2016-08-11 |
US9663524B2 (en) | 2017-05-30 |
EP2968337A4 (fr) | 2016-10-19 |
MA38393A3 (fr) | 2018-05-31 |
CN105307657A (zh) | 2016-02-03 |
EP2968337B1 (fr) | 2021-07-21 |
EP2968337A1 (fr) | 2016-01-20 |
BR112015022191A2 (pt) | 2017-10-10 |
JP2016519673A (ja) | 2016-07-07 |
CN111793068A (zh) | 2020-10-20 |
EA036160B1 (ru) | 2020-10-08 |
AU2014228746A1 (en) | 2015-09-10 |
SG11201507478VA (en) | 2015-10-29 |
KR20150131237A (ko) | 2015-11-24 |
KR102219695B1 (ko) | 2021-02-25 |
EA201591420A1 (ru) | 2016-02-29 |
WO2014144737A1 (fr) | 2014-09-18 |
JP6576325B2 (ja) | 2019-09-18 |
AU2014228746B2 (en) | 2018-08-30 |
PE20151776A1 (es) | 2015-12-11 |
CN105307657B (zh) | 2020-07-10 |
US20160046634A1 (en) | 2016-02-18 |
BR112015022191A8 (pt) | 2018-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38393A3 (fr) | Composés hétéroaryle et utilisations associées | |
TN2015000417A1 (en) | Heteroaryl compounds and uses thereof | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
EA202091709A1 (ru) | Ингибиторы днк-пк | |
BR112022002698A2 (pt) | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 | |
MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MA39898B1 (fr) | Composés 4-amino-imidazoquinoline | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
CA2871471C (fr) | Inhibiteurs d'adn pk | |
JO3181B1 (ar) | مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود | |
EA201101341A1 (ru) | Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе | |
EA200901157A1 (ru) | Конденсированные кольцевые гетероциклические модуляторы киназы | |
EA201100077A1 (ru) | Производные пиримидина в качестве ингибиторов киназы | |
GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
EA202091708A1 (ru) | Ингибиторы днк-пк | |
EA201691397A1 (ru) | Хинолиновые ингибиторы киназы | |
EA200800374A1 (ru) | 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции | |
EA201590268A1 (ru) | Ариллактамные ингибиторы киназы | |
EA201100078A1 (ru) | Производные пиримидина в качестве ингибиторов киназы | |
EA201501187A1 (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний | |
MX2009012079A (es) | Compuestos heterociclicos condensados como inhibidores de proteina cinasas. | |
WO2016004280A3 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
EA201792676A1 (ru) | Ингибиторы jak1 |